Non profit organsiation GARDP (Global Antibiotic Research and Development Partnership) said it wants to collaboratively develop 5 drug that break antibiotic resistance by 2025, one more than announced at its launch by the World Health Organisation and the Drugs for Neglected Diseases initiative (DNDi). “We are in a race against time to develop new antibiotics and make them accessible to the millions of people who need them," said Professor Ramanan Laxminarayan, Chair of the Global Antibiotic Research and Development Partnership (GARDP) at a conference at Geneva. "GARDP’s remarkable progress over the last three years in building strong partnerships and a talented team positions it well to meet this ambitious new goal. We need to work together with all stakeholders, including governments, academia and civil society, philanthropic organizations and the private sector, to make this goal a reality.”
GARDP said its five treatments will focus on the priority bacterial pathogens identified by the World Health Organization (WHO). GARDP claimed "alarming levels of resistance" were reported in countries "of all income levels". According to the O’Neill report, drug-resistant bugs already cause at least 700,000 deaths globally per year, mostly in the global south who can't afford new treatments. In developed countries, AMR mostly occurs through opportunistic infections at hospitals. According to the CDC, every year 25,000 US-Americans die due to antimicrobial resistance; the ECDC reported a raise from 25,000 to 33,000 deaths in Europe during the last decade. In India, hundreds of thousands of newborns are dying of sepsis, for which still there is no causative treatment available. GARDP said, AMR would be key to achieving Universal Health Coverage and meeting the Sustainable Development Goals.